Assessment of Hypoxia and Perfusion in Human Brain Tumors Using PET with 18F-fluoromisonidazole and 15O-H2O
Overview
Affiliations
Unlabelled: Hypoxia predicts poor treatment response of malignant tumors. We used PET with (18)F-fluoromisonidazole ((18)F-FMISO) and (15)O-H(2)O to measure in vivo hypoxia and perfusion in patients with brain tumors.
Methods: Eleven patients with various brain tumors were investigated. We performed dynamic (18)F-FMISO PET, including arterial blood sampling and the determination of (18)F-FMISO stability in plasma with high-performance liquid chromatography (HPLC). The (18)F-FMISO kinetics in normal brain and tumor were assessed quantitatively using standard 2- and 3-compartment models. Tumor perfusion ((15)O-H(2)O) was measured immediately before (18)F-FMISO PET in 10 of the 11 patients.
Results: PET images acquired 150-170 min after injection revealed increased (18)F-FMISO tumor uptake in all glioblastomas. This increased uptake was reflected by (18)F-FMISO distribution volumes >1, compared with (18)F-FMISO distribution volumes <1 in normal brain. The (18)F-FMISO uptake rate K(1) was also higher in all glioblastomas than in normal brain. In meningioma, which lacks the blood-brain barrier (BBB), a higher K(1) was observed than in glioblastoma, whereas the (18)F-FMISO distribution volume in meningioma was <1. Pixel-by-pixel image analysis generally showed a positive correlation between (18)F-FMISO tumor uptake at 0-5 min after injection and perfusion ((15)O-H(2)O) with r values between 0.42 and 0.86, whereas late (18)F-FMISO images (150-170 min after injection) were (with a single exception) independent of perfusion. Spatial comparison of (18)F-FMISO with (15)O-H(2)O PET images in glioblastomas showed hypoxia both in hypo- and hyperperfused tumor areas. HPLC analysis showed that most of the (18)F-FMISO in plasma was still intact 90 min after injection, accounting for 92%-96% of plasma radioactivity.
Conclusion: Our data suggest that late (18)F-FMISO PET images provide a spatial description of hypoxia in brain tumors that is independent of BBB disruption and tumor perfusion. The distribution volume is an appropriate measure to quantify (18)F-FMISO uptake. The perfusion-hypoxia patterns described in glioblastoma suggest that hypoxia in these tumors may develop irrespective of the magnitude of perfusion.
Jochumsen M, Christensen N, Iversen P, Gormsen L, Sorensen J, Tolbod L Eur J Nucl Med Mol Imaging. 2024; 51(13):4134-4140.
PMID: 38940842 PMC: 11527927. DOI: 10.1007/s00259-024-06799-3.
PET Imaging of Metabolism, Perfusion, and Hypoxia: FDG and Beyond.
Pantel A, Bae S, Li E, OBrien S, Manning H Cancer J. 2024; 30(3):159-169.
PMID: 38753750 PMC: 11101148. DOI: 10.1097/PPO.0000000000000716.
Wang Y, Fushimi Y, Arakawa Y, Shimizu Y, Sano K, Sakata A Jpn J Radiol. 2023; 41(11):1255-1264.
PMID: 37219717 PMC: 10613590. DOI: 10.1007/s11604-023-01450-x.
Advances in PET and MRI imaging of tumor hypoxia.
Gouel P, Decazes P, Vera P, Gardin I, Thureau S, Bohn P Front Med (Lausanne). 2023; 10:1055062.
PMID: 36844199 PMC: 9947663. DOI: 10.3389/fmed.2023.1055062.
Imaging of hypoxia in human glioblastoma with dynamic 18F-fluoromisonidazole PET.
Abdo R, Lamare F, Fernandez P, Bentourkia M Cancer Drug Resist. 2022; 2(1):131-140.
PMID: 35582145 PMC: 9019176. DOI: 10.20517/cdr.2018.21.